Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy
| Status: | Archived |
|---|---|
| Conditions: | Post-Surgical Pain, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Musculoskeletal |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
| End Date: | September 2011 |
A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy
This study will assess pain intensity for the first 72 hrs after after aggravated movement
(cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the
CollaRx Bupivacaine implant or a plain collagen sponge.
Inguinal herniorrhaphy is a common surgery; and common surgical methods used include
laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly
reduce the risk of hernia recurrence regardless of the method used for its placement.
Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain
considerable medical challenges.
Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile.
Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a
thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine.
When inserted into a surgical site, the collagen breaks down and bupivacaine is released at
the site but very little is absorbed into the blood stream. The high levels of bupivacaine
at the surgical site may result in less pain for several days after surgery.
This study will assess pain intensity after surgery in patients who receive either the
CollaRx Bupivacaine implant or a plain collagen sponge.
We found this trial at
1
site
Click here to add this to my saved trials
